NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...

Company's once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management ALAMEDA, Calif., ...

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...

Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company's once or twice-yearly GLP-1 (semaglutide) implant ...

Vivani Medical, Inc. (VANI), on Wednesday, announced promising preclinical data for its semaglutide implant in development ...

Two-year data from a phase 3 trial of exenatide in Parkinson’s is due later this year and could help answer that question, said Prof Foltynie.

GLP-1 receptor agonists, originally introduced in 2006, have undergone significant advancements over the years. David Ricks, ...

Nausea is a common occurrence for people with diabetes. In some cases, it could be a sign of a life threatening condition that requires swift medical attention. Nausea can take many forms ...

Just because a research project sounds like a waste of money to people who know nothing of the topic, doesn’t mean it won’t ...

After hours: March 26 at 7:58:02 PM EDT Loading Chart for VANI ...